Structural Basis of Shiga Toxin Neutralization by Human Antibodies Targeting Canonical Receptor‐Binding and Non‐Canonical Assembly Sites
Advanced Science · 30.08.2026
DOI: 10.1002/advs.77402 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 30.08.2026. Verfasst von Jianting Ke und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, People's Republic of China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antibodies, Neutralizing, Shiga Toxin, Shiga-Toxigenic Escherichia coli. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Science and Technology Major Project, Sun Yat-sen University supporting grant.
Abstract (Originalsprache)
Shiga toxin‐producing Escherichia coli (STEC) infections cause severe systemic complications, yet targeted antitoxin therapeutics remain an unmet clinical need. Here, we isolated a panel of human monoclonal antibodies (mAbs) targeted at STEC toxin and characterized two potent neutralizing candidates, RDS045 and RDS059. The cryo‐electron microscopy structure of the human mAb RDS059 in complex with the Shiga toxin 1a B subunit (Stx1aB) reveals that RDS059 recognizes the surface‐exposed loop of Stx1aB, whereby it directly competes with the host glycolipid globotriaosylceramide (Gb3) to block toxin‐cell engagement. In contrast, RDS045 binds a non‐canonical quaternary epitope at the pentameric interface of Stx1aB, acting as an interprotomer clamp via an extensive hydrogen‐bonding and cation‐π interaction network. Both antibodies confer robust protection in cellular assays and an in vivo murine Stx1a challenge model. Collectively, this work defines two distinct molecular blueprints for Shiga toxin receptor blockade and assembly interference, establishing mechanistic frameworks for the development of STEC therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, People's Republic of China.
- Department of Experimental Research, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, People's Republic of China.
- Zhuhai Trinomab Pharmaceutical Co., Ltd, Zhuhai, Guangdong, People's Republic of China.
- NHC Key Laboratory of Clinical Nephrology, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China.
- State Key Laboratory of Anti-Infective Drug Discovery and Development, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.
- Guangdong Engineering Research Center of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Engineering Technology Research Center of Molecular Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuh…
ORCID-Profile: Xin Li, Cheng Wang, Shoudeng Chen
Förderung
- National Natural Science Foundation of China
- National Science and Technology Major Project
- Sun Yat-sen University supporting grant
Zitieren
APA
Ke, J., Li, X., Wang, X., Huang, Z., Xue, S., Liu, Y., Pan, J., Hu, G., Wang, Y., Wang, C., & Chen, S. (2026). Structural Basis of Shiga Toxin Neutralization by Human Antibodies Targeting Canonical Receptor‐Binding and Non‐Canonical Assembly Sites. Advanced Science. https://doi.org/10.1002/advs.77402
Vancouver
Ke J, Li X, Wang X, Huang Z, Xue S, Liu Y, et al. Structural Basis of Shiga Toxin Neutralization by Human Antibodies Targeting Canonical Receptor‐Binding and Non‐Canonical Assembly Sites. Advanced Science. 2026. doi:10.1002/advs.77402
BibTeX
@article{Ke2026,
author = {Ke, Jianting and Li, Xin and Wang, Xiaoli and Huang, Zhaoxia and Xue, Shaojie and Liu, Yuyang and Pan, Jing and Hu, Guowei and Wang, Yayu and Wang, Cheng and Chen, Shoudeng},
title = {Structural Basis of Shiga Toxin Neutralization by Human Antibodies Targeting Canonical Receptor‐Binding and Non‐Canonical Assembly Sites},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.77402}
}
EUVIMED